(RDNT) RadNet - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7504911022
RDNT: Medical Imaging, Artificial Intelligence, Diagnostic Services
RADNET (NASDAQ:RDNT) operates as a leading provider of outpatient diagnostic imaging services across the United States. With a strong market position in high-demand regions like California and the Northeast, the company has built a scalable platform that combines traditional imaging services with cutting-edge AI-driven diagnostic tools. Founded in 1981, RadNet has established itself as a key player in the diagnostics space, with a market capitalization of over $4.6 billion, reflecting its scale and growth prospects.
The company’s core business revolves around its Imaging Centers segment, which offers a wide range of diagnostic services, including MRI, CT scans, PET scans, mammography, ultrasound, and fluoroscopy. This diversified service offering allows RadNet to cater to a broad patient base, making it a one-stop solution for outpatient imaging needs. The company’s extensive network of imaging centers ensures high accessibility and convenience for both patients and healthcare providers.
What sets RadNet apart is its growing focus on Artificial Intelligence. The company has made significant strides in developing AI-powered solutions designed to enhance radiologist workflows and improve diagnostic accuracy. For instance, its AI suites are specifically tailored to improve the interpretation of breast, lung, and prostate images, addressing some of the most critical areas in cancer screening. This integration of AI not only enhances patient outcomes but also positions RadNet as a forward-thinking leader in the diagnostics industry.
From a financial perspective, RadNet’s valuation metrics highlight its growth trajectory. With a price-to-sales ratio of 2.62 and a price-to-book ratio of 5.19, the company is trading at a premium, reflecting investor confidence in its ability to scale and innovate. While the current P/E ratio is not meaningful due to earnings volatility, the forward P/E suggests expectations of improving profitability as the company continues to consolidate its market position and expand its AI offerings.
For investors and fund managers, RadNet represents a compelling opportunity to invest in the intersection of healthcare and technology. The company’s strong market position, recurring revenue model, and strategic focus on AI-driven innovation make it a standout player in the diagnostics space. As the healthcare industry continues to shift toward value-based care and precision medicine, RadNet is well-positioned to benefit from these trends, making it a strategic addition to portfolios with a long-term horizon.
Additional Sources for RDNT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
RDNT Stock Overview
Market Cap in USD | 3,819m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1986-07-01 |
RDNT Stock Ratings
Growth 5y | 78.7% |
Fundamental | 23.2% |
Dividend | 0.0% |
Rel. Strength Industry | 5.16 |
Analysts | 4.5/5 |
Fair Price Momentum | 46.94 USD |
Fair Price DCF | 9.06 USD |
RDNT Dividends
No Dividends PaidRDNT Growth Ratios
Growth Correlation 3m | -91.8% |
Growth Correlation 12m | 58.9% |
Growth Correlation 5y | 81% |
CAGR 5y | 34.55% |
CAGR/Max DD 5y | 0.57 |
Sharpe Ratio 12m | -0.17 |
Alpha | -6.82 |
Beta | 1.34 |
Volatility | 61.44% |
Current Volume | 1140.3k |
Average Volume 20d | 914k |
As of March 15, 2025, the stock is trading at USD 46.54 with a total of 1,140,338 shares traded.
Over the past week, the price has changed by -7.49%, over one month by -24.12%, over three months by -40.32% and over the past year by +6.09%.
Neither. Based on ValueRay Fundamental Analyses, RadNet is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 23.22 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RDNT as of March 2025 is 46.94. This means that RDNT is currently overvalued and has a potential downside of 0.86%.
RadNet has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy RDNT.
- Strong Buy: 3
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, RDNT RadNet will be worth about 52 in March 2026. The stock is currently trading at 46.54. This means that the stock has a potential upside of +11.82%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 77.7 | 66.9% |
Analysts Target Price | 90.2 | 93.7% |
ValueRay Target Price | 52 | 11.8% |